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Purpose of the study
The nucleoside reverse transcriptase inhibitor abacavir is
prescribed, in combination with other drugs, for the treat-
ment of HIV-1. Roughly 4–8% of patients receiving
abacavir experience a hypersensitivity reaction (HSR),
which usually appears within 6 weeks of treatment initia-
tion. Several studies have demonstrated the association
between abacavir HSR and the human leukocyte antigen
(HLA)-B*5701. Therefore, systematic HLA-B*5701
screening prior to abacavir prescription enables clinicians
to establish individual HSR susceptibility, and conse-
quently increase the safety profile of HIV treatment. The
objective of this study was to analyse if systematic HLA-
B*5701 screening to prevent abacavir HSR is a cost-effec-
tive option in the Spanish National Health System (NHS).
Methods
A decision analytical model was built to compare if sys-
tematic HLA-B*5701 screening to prevent abacavir HSR is
a cost-effective option compared to no screening, from the
NHS perspective. Clinical parameters of the model and
health resources use during HSR were derived from PRE-
DICT-1 study and local clinical expert opinion. The pri-
mary result of the study was incremental cost per HSR
avoided. All costs were expressed in 2007 euros. Model
uncertainty was assessed through a sensitivity analysis
which included different scenarios depending on antiret-
roviral regimens, and univariate sensitivity analysis to
study the influence of key parameters in the model like as
HLA-B*5701 test cost.
Summary of results
The analysis showed that total direct health costs (drug
costs, test cost and HSR management costs) were 1,344 €
and 1,322 € for HLA-B*5701 screening and no screening,
respectively (an additional cost of 22 € per patient), with
a reduction of approximately 36 HSR per 1,000 patients
screened (42 and 78 HSR/1,000 patients, respectively).
These results yielded to a cost per HSR avoided of 630 €.
Results were not sensitive to drug regimen changes, but
they were influenced by test cost, causing cost savings or a
maximum additional cost per patient of 150 € (based on
a test cost of 29 €-183 €). Using extreme values for antiret-
roviral regimens and test costs, the incremental cost per
HSR avoided of systematically testing all patients ranged
from cost savings (when test cost is 29 €) to 4,234 €
(when test cost is 183 €).
Conclusion
Systematic HLA-B*5701 screening prior to abacavir pre-
scription in HIV patients is associated with a limited addi-
tional cost that could be offset by its benefits in terms of
lower HSR incidence.
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